Diabetes devicemaker Medtronic has invested in the Glooko diabetes platform. The “strategic investment” described by MobiHealthNews is part of the $16.5 million Glooko recently raised from investors including The Social + Capital Partnership and Samsung.

Interested in beyond-the-pill pacts? More info here.  

Glooko’s first product was a cord that connected a range of glucometers to a smartphone, but it has since expanded to include a wireless sync using Bluetooth technology. The company has also teamed up with healthcare organizations like the Harvard Medical School-affiliated Joslin Diabetes Center to create a HypoMap program that pulls data from activity monitors and glucometers.

Glooko’s CEO told MobiHealth that it will be modifying its platform so it can work with data from Medtronic’s insulin pumps and continuous glucose monitoring devices.